UK NHS Launches Advanced 5‑Dose Radiotherapy for Prostate Cancer

On 6 September 2026 the NHS announced that all 48 radiotherapy centres in England will begin offering stereotactic ablative radiotherapy (SABR) for low‑ and intermediate‑risk prostate cancer patients. SABR delivers high‑powered, highly targeted radiation in a typical five‑dose course, compared to the 20 or more fractions used in conventional therapy.

Health officials say the treatment’s precision allows clinicians to spare surrounding healthy tissue while still destroying cancer cells. The technology is already in use for lung, brain and other cancers. The NHS’s new roll‑out is the first time it will be offered to prostate cancer patients outside of clinical trials.

Modelling suggests roughly 17,500 men diagnosed each year in England with low or intermediate risk may benefit. Only about a fifth of that group—around 3,500 men—are projected to choose SABR, largely because many low‑risk men opt for active surveillance rather than immediate treatment. Nevertheless, the NHS believes the advanced protocol will transform care for thousands of men.

Senior medical leaders highlighted the benefits. Prof Peter Johnson, NHS England’s national clinical director for cancer, said the powerful beam limits damage to healthy cells and reduces the typical 15‑dose gap between treatments. “This technology lets us focus a powerful and precise beam of radiotherapy directly on to the cancer, limiting the damage to healthy cells. And the fact it can be delivered in 15 fewer doses will help men get back to living their lives far more quickly,” he told the media.

Sir Jim Mackey, NHS chief executive, added that the £70m investment in new linear accelerator machines is part of the National Cancer Plan for England. “Backed by the Government’s investment, this treatment targets tumours with greater accuracy, helping reduce side‑effects and enabling many patients to complete their treatment in a fraction of the time compared with conventional radiotherapy.”

Patient stories illustrate the impact. Edwin Lambert, 70, from Suffolk, had already undergone hormone therapy for prostate cancer and experienced fatigue and loss of libido. After receiving SABR, he reported fewer side‑effects and returned to normal activities within weeks. “This treatment was an absolute godsend,” he said.

While the policy will not benefit all prostate cancer patients—particularly those with high‑risk disease—clinical trials are underway to test SABR on this group. The NHS also remains cautious about screening, reflecting the UK National Screening Committee’s recommendation for targeted testing only for men with genetic risk factors.

Overall, the NHS’s decision to offer SABR to low‑ and intermediate‑risk prostate cancer patients represents a significant step in delivering high‑quality, patient‑focused care. By reducing treatment sessions from 20 to five, men can avoid the repetitive, often exhausting hospital visits typical of conventional radiotherapy and recover faster.